La Jolla Pharmaceutical Co (LJPC) Stock
LJPC is no longer traded. La Jolla Pharmaceutical was delisted from the Nasdaq in August 2022.
Prices on this page are historical; the last trade was August 18, 2022 at $6.22.
La Jolla Pharmaceutical stock price history
LJPC final trading statistics
- Final close
- $6.22
- Final trading day
- Aug 18, 2022
- Market cap at delisting
- $155.11M
- Shares outstanding
- 24.94M
- Final 52-week range
- $3.07 – $6.22
- Avg. volume (final 3 mo.)
- 292,691
- All-time high (split-adj.)
- $1000000.00 · Jun 1994
- All-time low (split-adj.)
- $2.00 · Mar 2012
- Return since IPO
- -100.0%
- Beta
- 2.41
- Book value / share
- -$0.61
- Price / book
- -10.23
La Jolla Pharmaceutical annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $75.72M | $19.7M | $0.57 |
| FY2020 | $33.42M | -$39.4M | -$1.45 |
| FY2019 | $23.05M | -$116.5M | -$4.30 |
| FY2018 | $10.06M | -$199.5M | -$7.90 |
| FY2017 | $0.00 | -$114.8M | -$5.40 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About La Jolla Pharmaceutical Co
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.
La Jolla Pharmaceutical stock FAQ
What happened to La Jolla Pharmaceutical stock?
La Jolla Pharmaceutical stock was delisted from the Nasdaq. Its final close was $6.22 on August 18, 2022.
Is LJPC stock still trading?
No. LJPC was delisted from the Nasdaq in August 2022 and no longer trades on a U.S. exchange.
What was the last price of LJPC stock?
LJPC closed at $6.22 on its final trading day, August 18, 2022, for a market value of about $155.11M.
What were La Jolla Pharmaceutical's revenue and earnings in its last full fiscal year?
La Jolla Pharmaceutical reported revenue of $75.72M and net income of $19.7M in fiscal 2021, its last full year as a public company.
When did La Jolla Pharmaceutical go public?
La Jolla Pharmaceutical Co stock began trading on June 3, 1994.